IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory Myeloma

IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory Myeloma
Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24
Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24
Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24
Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24
Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24
Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24
Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH241
Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24
Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24
Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24
Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24
Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24
Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24
Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24
Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24
MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24
MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24
Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24
Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24
Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24
Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24
Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24
Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24